Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biogen
Biotech
Biogen to take Spinraza follow-up into registrational studies
Salanersen could help children with spinal muscular atrophy who are still struggling to sit independently despite having received Zolgensma.
James Waldron
Jun 25, 2025 8:04am
Biogen blueprints $1B CNS deal with RNAi biotech
May 27, 2025 10:55am
Biogen pays Stoke $165M, bagging Dravet drug to fire up pipeline
Feb 18, 2025 9:28am
Biogen axes asset from $7.3B buyout, plus Alzheimer’s prospect
Feb 12, 2025 9:53am
Biogen taps Royalty for $250M to fund phase 3 lupus program
Feb 12, 2025 8:10am
Atalanta loads crossbow with $97M, 2 Big Pharmas in tow
Jan 28, 2025 7:00am
